FDAsafety guidance66% confidence
Search for Regulatory References | Drugs
Source: FDA
Why This Matters
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Daiichi Sankyo; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Oncology · FLT3 Inhibitor
- Sub-indication
- General
Related signal: FDA Accepts Supplement Application for VANFLYTA (Quizartinib)